Virtual Library
Start Your Search
L. Shank
Author of
-
+
P3.04 - Poster Session/ Biology, Pathology, and Molecular Testing (ID 235)
- Event: WCLC 2015
- Type: Poster
- Track: Biology, Pathology, and Molecular Testing
- Presentations: 1
- Moderators:
- Coordinates: 9/09/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)
-
+
P3.04-097 - Expression of GM2 Activator Protein as a Potential Biomarker for Lung Cancer (ID 2206)
09:30 - 09:30 | Author(s): L. Shank
- Abstract
Background:
Lung cancer is a leading cause of cancer-related worldwide. Finding effective biomarkers for early diagnosis would be useful for potential curative treatment. GM2activator protein (GM2AP) is a glycoprotein acting as a cofactor for gangliosideGM2 degradation. GM2AP also associated with the changing levels of ganglioside which has role in tumor invasion, progression and metastases. This study aims to investigate and validate the potential of GM2AP as a lung cancer biomarker.
Methods:
The study was done from September 2011 to June 2013. Serum and urine samples were obtained from lung cancers patients and healthy volunteers from Thailand and Taiwan. The expression level of GM2AP was using two-dimensional gel electrophoresi (2-DE), Western blotting and enzyme linked immunosorbine ent assay (ELISA). This studly was approved by the local research ethics committee . Statistical analysis was performed using SPSS version 17.0. Paired samples t-test and one-way analysis of variance (ANOVA) were used to analyze in different groups. A confidential level of 95% (P<0.05) was consider statistically significant.
Results:
Thailand data There were total 48 lung cancer patients (male 33, female 15) and 44 healthy volunteers . The mean age of study cases and controlled group were 53.3 years (range 2-74) and 42.1 years (range 25-74) respectively. The mean of GM2AP level in lung cancer patiens was 1.60+/-1.21 ng/mL, whereas in healthy controls the levels was 0.21+/-0.14 ng/mLThe expression levels of urine and serum GM2AP were significantly increased when compared to those from healthy controls (P<0.05). The urine GM2AP level of lung cancer patients was 7.62+/-1.06 fold on the median. Moreover the urinary GM2AP level in the male patients (1.16+/-1.07 ng/mL) was higher than in female patients (1.13 +/-1.05 ng/mL). According to histologic subtype, the urinary GM2AP level measured in patents with adenocarinoma, small cell carcinoma and sqaumous cell carcinoma were 1.25+/-1.12, 1.48+/-1.35 and 2.27+/-2.20 ng.ml, respectively. From ROC curve of urinary GM2AP showed sensitivity of 90.91% and specificity of 91.67%.The expression levels of GM2AP of all patiens were included in the statistical analysis and significant correlation (P<0.05) was found with histology cancer types, whereas gender and pathological stage were not correlated. Taiwan data There were 133 lung cancer patients (male 60,female 73) with a mean age of 62 (range 30-81 years). The mean urinary GM2AP level in lung cancer patients was 1.46+/-1.55 ng/mL where as in controlled group was 0.18+/-0.19 ng/mL. There was a 8.03 +/- 1.36 fold increase of GM2AP level in urine and a 5.41+/-0.73 ng/mL. increase in the serum compared to the controlled group. From ROC curve provides 88.46% sensivity and 85.71% specificity in urine G2AP. The mean seum GM2AP level was 0.92+/- 0.27 and controlled group was 0.17+/-0.07 ng/mL. The ROC curve from serum G2AP provides 100% sensitivity and 82.71% specificity. No difference was shown in urinary or serum GM2AP levels when stratified by gender, smoking status , EGFR status or histology subtypes except for the pathology stage.
Conclusion:
Our data suggest that the GM2AP may be useflul as a biomarker for early diagnostic and prognostic in lung cancer.
